

Conformational Studies. Part 2.¹ Synthesis of 17 β -Hydroxy-4,4-dimethyl-5 α -androstan-3-one, and of the 19-Nor-analogue

By John M. Midgley, W. Basil Whalley,* and (in part) Patricia A. Dodson, Gerald F. Katekar, and Bruce A. Lodge, The School of Pharmacy, The University, London WC1N 1AX

Prepared from 17 β -hydroxy-5 α -androstan-3-one by C-4 methylation of 17 β -(tetrahydropyran-2-yloxy)-2,2-trimethylenedithio-5 α -androstan-3-one. 17 β -hydroxy-4,4-dimethyl-5 α -androstan-3-one (1; R¹ = Me, R² = H), exhibited a negative o.r.d. curve, and was identical with the hydrogenation product of 17 β -hydroxy-4,4-dimethyl-androst-5-en-3-one (2; R¹ = Me, R² = H). 17 β -Hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H) was similarly synthesised from 17 β -hydroxy-19-nor-5 α -androstan-3-one and also had a negative o.r.d. curve. However, contrary to previous reports, hydrogenation of 17 β -hydroxy-4,4-dimethyl-19-nor-androst-5-en-3-one (2; R¹ = R² = H) did not furnish the androstane (1; R¹ = R² = H) but a mixture of (1; R¹ = R² = H) and the 5 β -diastereoisomer which was difficult to separate; both these products exhibit negative o.r.d. curves. The physical constants of various cognate derivatives of (1; R¹ = R² = H), reported values of which are probably those of mixtures, have been clarified.

8-Nortestosterone has been converted into 17 β -hydroxy-4,4-dimethyl-8-nor-5 α -androstan-3-one. The preparation of various steroidal 2-butylthiomethylene-3-ones is reported.

As part of a general investigation into conformational problems, particularly those relating to 4,4-dimethyl-3-oxo-5 α -steroids and derivatives, we required authentic samples of 17 β -hydroxy-4,4-dimethyl-5 α -androstan-3-one (1; R¹ = Me, R² = H) and the 19-nor-analogue (1;

R¹ = R² = H) for o.r.d. and X-ray crystallographic investigations.

It has been established² that hydrogenation of 4,4-dimethylcholest-5-en-3-one furnishes predominantly the corresponding 5 α -derivative: hydrogenation of 17 β -hydroxy-4,4-dimethyl-androst-5-en-3-one (2; R¹ = R² = H) has been assumed³ to proceed similarly to yield the

¹ Part 1, M. J. T. Robinson and W. B. Whalley, *Tetrahedron*, 1963, **19**, 2123


² J. L. Beton, E. G. Halsall, E. R. H. Jones, and I. C. Phillips, *J. Chem. Soc.*, 1957, 753

³ H. J. Ringold and G. Rosenkranz, *J. Org. Chem.*, 1957, **22**, 602.

5 α -androstane (1; R¹ = Me, R² = H), and our present work confirms this conclusion.

The authenticity of the substance claimed⁴ to be 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H) is, however, uncertain. By analogy with the androstane series it has been assumed⁴ (but not proven) that methylation of 19-nortestosterone yields 17 β -hydroxy-4,4-dimethyl-19-norandrost-5-en-3-one (2; R¹ = R² = H), and that hydrogenation⁴ of this gives 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H). Since the evidence for the structure (1; R¹ = R² = H) and hence for those of its various derivatives⁴ is not beyond question, we have devised an unambiguous synthesis. Our results confirm the doubts which prompted our investigation.

Thus, the 2-hydroxymethylene derivative⁵ of 17 β -hydroxy-5 α -androstan-3-one was converted by the action² of *SS*-trimethylene 1,3-bis(toluene-*p*-thiosulphonate) into the spiro-dithian (3; R¹ = H, R² = Me).



However, the rigorous conditions required for C-4 methylation caused *O*-methylation at the C-17 hydroxy-group: to avoid this complication the 17 β -hydroxy-group was protected by forming the tetrahydropyranyl ether. Dimethylation of this tetrahydropyranyl ether with methyl iodide-potassium *t*-butoxide, followed by removal of the tetrahydropyranyl substituent with acid, gave the 4,4-dimethyl-2-dithioacetal (3; R¹ = R² = Me). The derived 17 β -acetate was desulphurised with Raney

* We are grateful to Professor N. L. Allinger for this information.

⁴ A. Bowers and H. J. Ringold, *J. Amer. Chem. Soc.*, 1959, **81**, 424.

⁵ R. O. Clinton, A. J. Manson, F. W. Stonner, H. C. Neumann, R. G. Christiansen, R. L. Clarke, J. H. Ackerman, D. F. Page, J. W. Dean, W. B. Dickinson, and C. Carabateas, *J. Amer. Chem. Soc.*, 1961, **83**, 1478.

nickel, and traces of 3-ols in the product were removed by oxidation (Jones reagent) to yield 17 β -hydroxy-4,4-dimethyl-5 α -androstan-3-one (1; R¹ = Me, R² = H) and the acetate (1; R¹ = Me, R² = Ac), which were identical with the corresponding derivatives prepared by hydrogenation of 17 β -hydroxy-4,4-dimethylandrost-5-en-3-one (2; R¹ = Me, R² = H) and acetylation. We did not achieve the catalytic hydrogenation of (2; R¹ = Me, R² = H) to (1; R¹ = Me, R² = H) by the published method,³ but a modification * with 1:1 acetic acid-cyclohexane containing a trace of perchloric acid as solvent functioned satisfactorily. Unequivocal, independent confirmation of the structure of compound (1; R¹ = Me, R² = H) has been provided by *X*-ray crystallography.⁶

The 19-nor-analogue was prepared similarly, from 19-nor-5 α -androstan-3-one by way of the spirodithian (3; R¹ = R² = H). In this case methylation at C-4 proceeded more readily (in the absence of C-19) to yield substantial quantities of the 4,4-dimethyl-derivative (3; R¹ = Me, R² = H) with only minor amounts of *O*-methylation at C-17: hence protection of the 17 β -hydroxy-group was unnecessary. Desulphurisation of the 17 β -acetate of this dithian followed by oxidation of the product with Jones reagent furnished, after hydrolysis, 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H), the structure of which was confirmed by *X*-ray crystallography.⁶ The corresponding 17 β -methyl ether was obtained similarly.

An alternative, more expeditious route to (1; R¹ = R² = H) commenced from 4-methyl-19-nortestosterone.⁷ Reduction of this with lithium-liquid ammonia followed by trapping of the resultant enolate with methyl iodide furnished (1; R¹ = R² = H) in high yield. After the completion of our work, the same technique was reported by Stork *et al.*⁸

With authentic 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one-17 β -ol available, we examined the published synthesis.⁴ Thus, methylation of 19-nortestosterone gave 4,4-dimethyl-19-norandrost-5-en-3-one, τ 9.19 (3 H, s, H₃-18), 8.78 (3 H, s, H₃-4), 8.72 (3 H, s, H₃-4), 6.28 (1 H, t, *J* 8 Hz, H-17 α), and 4.32 (1 H, t, vinylic H-6). As in the androstane series, the reported hydrogenation procedure⁴ gave unsatisfactory results, but the modified technique * gave, after an extensive process of separation and purification (see Experimental section) 4,4-dimethyl-19-nor-5 α -androstan-3-one, identical with that prepared by the alternative method, together with an isomeric compound which we formulate as the corresponding 5 β -derivative (*cf.* ref. 9).

The product from this catalytic hydrogenation has previously⁴ been purified by a combination of chromatography and crystallisation. These methods failed to

⁶ G. Ferguson, E. W. Macauley, J. M. Midgley, J. M. Robertson, and W. B. Whalley, *Chem. Comm.*, 1970, 944.

⁷ N. W. Atwater, *J. Amer. Chem. Soc.*, 1960, **82**, 2847.

⁸ G. Stork, P. Rosen, N. Goldman, R. V. Coombs, and J. Tsuji, *J. Amer. Chem. Soc.*, 1965, **87**, 275.

⁹ G. R. Chaudhry, T. G. Halsall, and E. R. H. Jones, *J. Chem. Soc.*, 1961, 2725.

separate our hydrogenation product or a synthetic 1 : 1 mixture of the 5 α - and 5 β -derivatives, though g.l.c. showed that each mixture consisted of two components in approximately equal proportions. These results, together with the differences between the physical constants of our specimen of (1; R¹ = R² = H) and those recorded⁴ strongly suggest that the previous preparations, as already adumbrated, were of doubtful authenticity. This view was further confirmed by the oxidation of (1; R¹ = R² = H) to the corresponding 3,17-dione, which exhibits a characteristic double m.p., different from the single m.p. previously reported¹⁰ Since the forms of both m.p.s gave the requisite elemental analysis they were not solvated.

However, despite these doubts, the o.r.d. curves of our (1; R¹ = R² = H) are negative as previously reported. Fortuitously, the difference between the amplitude reported¹¹ and our value, together with the negative o.r.d. and the similarity between the amplitudes of the curves of the 5 α - and 5 β -derivatives, combine to leave unchanged the general conclusions¹⁰ concerning the conformation of (1; R¹ = R² = H).

17 β -Hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H) was converted by standard methods into 17 β -hydroxy-4,4,17 α -trimethyl-19-nor-5 α -androstan-3-one. The amplitude of the o.r.d. curve of this authentic preparation (—9) differed substantially from that reported¹¹ (—15).

To provide comparative data, which will be discussed in a later publication, B-nortestosterone was methylated to yield 17 β -hydroxy-4,4-dimethyl-B-norandrost-5-en-3-one (4). Hydrogenation of (4) gave a product which on general principles we formulate as the 5 α -derivative (5).

During exploratory investigations relevant to this work we sought to use steroidal alkylthiomethylene derivatives of type (6; R = BuⁿS) as substrates for C-4 methylation.¹² Previously,¹² these alkylthiomethylene derivatives have been prepared by acid-catalysed condensation of the appropriate α -hydroxymethylene ketone with the requisite (usually n-butyl) thiol. This process failed with 2 α -hydroxymethylene-3-oxo-5 α -steroids of type (6; R = OH), but proceeded readily with the corresponding 2-methoxymethylene derivatives of type (6; R = OMe) with butane-1-thiol. However these derivatives failed to be of use for our purpose, since, in contrast to the derivatives from decalones,¹² etc., they decomposed rapidly to intractable coloured products under the basic methylation conditions.

EXPERIMENTAL

Optical rotations and i.r. spectra were determined for solutions in chloroform unless otherwise stated; n.m.r. spectra were recorded for solutions in deuteriochloroform with a Varian A-60 spectrometer. Light petroleum refers to the fraction of b.p. 40–60 °C.

17 β -Hydroxy-4,4-dimethyl-5 α -androstan-3-one (1; R¹ =

Me, R² = H).—Prepared by condensation of 17 β -hydroxy-2-hydroxymethylene-5 α -androstan-3-one⁵ (0.5 g) with SS-trimethylene 1,3-bis(toluene-*p*-sulphonate) (0.5 g) in boiling benzene during 2 h, 17 β -hydroxy-2,2-trimethylenedithio-5 α -androstan-3-one formed needles (0.4 g), m.p. 215° (from methanol-acetone), $[\alpha]_D^{20} + 132^\circ$ (*c* 2.5) (Found: C, 66.8; H, 9.0; S, 16.1. C₂₂H₃₄O₂S₂ requires C, 66.9; H, 8.7; S, 16.3%), ν_{\max} . 3 470 (OH) and 1 700 cm⁻¹ (C=O).

A solution of this dithian (0.5 g) in tetrahydrofuran (5 ml) containing 2,3-dihydropyran (0.3 g) and toluene-*p*-sulphonic acid (5 mg) was heated at 100 °C for 1.5 h. Next day the product was isolated and purified from aqueous acetone containing a trace of pyridine to yield the 17 β -(tetrahydropyran-2-yl) ether in needles (0.37 g), m.p. 210–213°, $[\alpha]_D^{20} + 106^\circ$ (*c* 3.5) (Found: C, 67.7; H, 8.9; O, 10.1; S, 13.1. C₂₇H₄₂O₃S₂ requires C, 67.7; H, 8.8; O, 10.0; S, 13.4%), τ 9.23 (3 H, s, H₃-18) and 8.92 (3 H, s, H₃-19).

A solution of this pyranyl ether (1 g) in benzene (10 ml) was added to *t*-butyl alcohol (10 ml) containing potassium *t*-butoxide [from potassium (0.4 g)] in an atmosphere of nitrogen. Methyl iodide (0.3 ml) was added to the boiling solution and the refluxing continued for 0.25 h; further methyl iodide (0.3 ml) was then added. After refluxing for 15 min, more methyl iodide (0.6 ml) was introduced, and 15 min later the product was isolated and purified by chromatography from benzene-light petroleum (1 : 1) to yield 4,4-dimethyl-17 β -(tetrahydropyran-2-yloxy)-2,2-trimethylenedithio-5 α -androstan-3-one in needles (0.5 g), m.p. 166° (from methanol), $[\alpha]_D^{20} - 68^\circ$ (*c* 1.0) (Found: C, 68.9; H, 9.3; S, 12.5. C₂₈H₄₆O₃S₂ requires C, 68.8; H, 9.1; S, 12.7%), ν_{\max} . 1 685 cm⁻¹ ($\alpha\alpha\alpha'$ -tetrasubstituted C=O), τ 9.23 (3 H, s, H₃-18), 9.08 (3 H, s, H₃-19), 8.83 (3 H, s, 4-Me), and 8.60 (3 H, s, 4-Me).

A solution of this pyranyl ether (0.33 g) in ethanol (19 ml), water (1 ml), and concentrated hydrochloric acid (0.25 ml) was refluxed for 1.5 h. The product was purified from methanol-acetone to yield 17 β -hydroxy-4,4-dimethyl-2,2-trimethylenedithio-5 α -androstan-3-one (3; R¹ = R² = Me) in needles (0.23 g), m.p. 207°, $[\alpha]_D^{20} - 43^\circ$ (*c* 1.3) (Found: C, 68.8; H, 9.2; S, 15.0. C₂₄H₃₈O₂S₂ requires C, 68.2; H, 9.0; S, 15.2%), ν_{\max} . 3 550 and 3 430 (OH) and 1 685 cm⁻¹ (C=O), τ 9.27 (3 H, s, H₃-19), 9.08 (3 H, s, H₃-18), 8.83 (3 H, s, 4-Me), and 8.60 (3 H, s, 4-Me). Prepared quantitatively with pyridine-acetic anhydride the derived 17 β -acetate formed needles, m.p. 206° (from methanol-acetone), $[\alpha]_D^{20} - 50^\circ$ (*c* 1.6) (Found: C, 66.7; H, 8.6; S, 13.7. C₂₆H₄₀O₃S₂ requires C, 67.2; H, 8.7; S, 13.8%).

A solution of this acetate (0.8 g) in ethanol (70 ml) containing W-2-type Raney nickel (8 g) was refluxed for 6 h, and the product isolated and oxidised with Jones reagent to yield 17 β -acetoxy-4,4-dimethyl-5 α -androstan-3-one, which formed plates (0.4 g), m.p. 152–153° (from methanol), $[\alpha]_D^{20} - 16.3^\circ$ (*c* 2.0) (Found: C, 77.0; H, 10.3. Calc. for C₂₃H₃₆O₃: C, 76.7; H, 10.1%), ν_{\max} . 1 735 (ester) and 1 703 cm⁻¹ (C=O), τ 9.18 (3 H, s, H₃-19), 8.92 (9 H, s, H₃-18 and 4-Me₂), and 7.95 (3 H, s, Ac) (lit.,¹³ m.p. 150–152.5° for a specimen prepared by an alternative process).

¹¹ C. Djerassi, O. Halpern, V. Halpern, and B. Riniker, *J. Amer. Chem. Soc.*, 1958, **80**, 4001.

¹² R. E. Ireland and J. A. Marshall, *J. Amer. Chem. Soc.*, 1959, **81**, 6336; *J. Org. Chem.*, 1962, **27**, 1615, 1620; D. C. Aldridge, J. F. Grove, P. McCloskey, and W. Klyne, *J. Chem. Soc.*, 1963, 2569.

¹³ E. Kaspar and M. Schenck, Schering Akt-Ger., Ger. P., 1,023,765 (*Chem. Abs.*, 1960, **54**, 5756a).

¹⁰ N. L. Allinger and M. A. DaRooge, *J. Amer. Chem. Soc.*, 1962, **84**, 4561.

Hydrolysis of this acetate (0.5 g) in boiling methanol containing potassium hydroxide (0.1 g) during 15 h gave 17 β -hydroxy-4,4-dimethyl-5 α -androstan-3-one (0.4 g) in needles, m.p. 149° (from acetone–light petroleum), $[\alpha]_D^{20}$ –16.3° (*c* 2.0), identical with a specimen prepared by catalytic hydrogenation of 4,4-dimethylandrost-5-en-3-one {lit.³ m.p. 145–147°, $[\alpha]_D^{20}$ –13.7° (*c* 2.0)} (Found: C, 78.9; H, 10.7. Calc. for C₂₁H₃₄O₂: C, 79.2; H, 10.7%). Regenerated from this alcohol by way of the unstable 2-hydroxymethylene derivative, 17 β -hydroxy-4,4-dimethyl-2,2-trimethylenedithio-5 α -androstan-3-one (3; R¹ = R² = Me) was identical with an authentic specimen.

17 β -(Tetrahydropyran-2-yloxy)-5 α -androstan-3-one.—Prepared from 17 β -hydroxy-5 α -androstan-3-one (0.5 g) and 2,3-dihydropyran (0.3 g) in boiling tetrahydrofuran (5 ml) containing toluene-*p*-sulphonic acid (5 mg) during 1.5 h, the tetrahydropyranyl ether (0.5 g) formed plates, m.p. 146° (from aqueous acetone), $[\alpha]_D^{20}$ +97° (*c* 1.1) (Found: C, 76.8; H, 10.2. C₂₄H₃₈O₃ requires C, 77.0; H, 10.2%).

17 β -Methoxy-4 α -methyl-2,2-trimethylenedithio-5 α -androstan-3-one.—This compound was the only identified product from the methylation of 17 β -hydroxy-2,2-trimethylenedithio-5 α -androstan-3-one under various conditions. The following illustrates the method. A solution of the dithian (1 g) in benzene (10 ml) was added to *t*-butyl alcohol (10 ml) containing potassium *t*-butoxide [from potassium (0.5 g)]. After addition of methyl iodide (0.4 ml) the mixture was refluxed for 3 h. The crude product was purified from benzene by chromatography on alumina to yield the 4 α -methyl-17 β -methoxy-derivative which formed needles (0.25 g), m.p. 148°, $[\alpha]_D^{20}$ +81° (*c* 0.9) [Found: C, 68.8; H, 9.3; S, 15.1; OMe, 7.9. C₂₃H₃₅OS₂(OMe) requires C, 68.0; H, 9.2; S, 15.1; OMe, 7.3%], devoid of OH i.r. absorption, ν_{\max} . 1700 cm⁻¹ (C=O), τ 9.24 (3 H, s, H₃-18), 8.92 (3 H, s, H₃-19), 8.80 (3 H, d, *J* 7 Hz, 4-Me), and 6.66 (3 H, s, OMe).

17 β -Hydroxy-4,4-dimethyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one (3; R¹ = Me, R² = H).—A mixture of 17 β -hydroxy-2-hydroxymethylene-19-nor-5 α -androstan-3-one (1 g), *SS*-trimethylene 1,3-bis(toluene-*p*-sulphonate) (1.2 g), and sodium acetate (2.5 g) in ethanol (30 ml) was refluxed for 0.5 h under nitrogen. After 4 days the product was isolated in the usual manner and purified by chromatography from benzene on alumina to yield 17 β -hydroxy-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one (3; R¹ = R² = H) in prisms (0.65 g), m.p. 225–229°, $[\alpha]_D^{20}$ +245° (*c* 2.0) (Found: C, 66.9; H, 8.6; S, 16.6. C₂₁H₃₂O₂S₂ requires C, 66.3; H, 8.4; S, 16.9%). A solution of this dithian (1 g) in benzene (12 ml) was added to a warm solution of potassium *t*-butoxide [from *t*-butyl alcohol (15 ml) and potassium (0.5 g)] under nitrogen. The mixture was refluxed while methyl iodide (1.2 ml) was introduced during 15 min. Isolated in the usual manner, the product was purified by chromatography on alumina to yield [by elution with benzene–light petroleum (3 : 7)] 17 β -methoxy-4,4-dimethyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one, which formed needles (0.07 g), m.p. 156° (from methanol), $[\alpha]_D^{20}$ +138° (*c* 2.8) [Found: C, 68.5; H, 8.8; S, 14.8; OMe, 7.4. C₂₃H₃₅OS₂(OMe) requires C, 68.2; H, 9.1; S, 15.2; OMe, 7.3%], ν_{\max} . 1690 cm⁻¹ ($\alpha\alpha\alpha'$ -tetrasubstituted C=O), τ 9.20 (3 H, s, H₃-18), 8.81 (3 H, s, 4-Me), 8.74 (3 H, s, 4-Me), and 6.63 (3 H, s, OMe).

A solution of the foregoing dithian (0.5 g) in ethanol (40 ml) containing *W*-2-type Raney nickel (6 g) was refluxed for 5 h. After isolation a solution of the product in acetone was oxidised with Jones reagent to yield 17 β -methoxy-4,4-

dimethyl-19-nor-5 α -androstan-3-one, which separated from aqueous methanol in needles (0.3 g), m.p. 130°, $[\alpha]_D^{20}$ –20.9° (*c* 1.1), o.r.d. (*c* 0.26 in MeOH) $[\phi]_{500}^{20}$ –100°, $[\phi]_{400}^{20}$ –180°, $[\phi]_{313}^{20}$ –1000°, $[\phi]_{269}^{20}$ +680°, $[\phi]_{214}^{20}$ +250° [Found: C, 79.2; H, 10.8; OMe, 9.8. C₂₀H₃₁O(OMe) requires C, 79.2; H, 10.8; OMe, 9.8%], τ 9.21 (3 H, s, H₃-18), 8.94 (6 H, s, 4-Me₂), 6.64 (3 H, s, OMe).

Further elution of the column with benzene–ether (9 : 1) gave a semi-crystalline product (0.4 g) which could not be adequately purified and was acetylated. Chromatography of the crude acetate gave two major fractions. The first crystallised from ethanol–acetone to yield 17 β -acetoxy-4,4-dimethyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one in plates (0.2 g), m.p. 185°, $[\alpha]_D^{20}$ +120° (*c* 2.8) (Found: C, 66.7; H, 8.2; S, 14.2. C₂₃H₃₅O₃S₂ requires C, 66.6; H, 8.5; S, 14.2%), ν_{\max} . 1735 (acetate) and 1690 cm⁻¹ (C=O), τ 9.16 (3 H, s, H₃-18), 8.81 (3 H, s, 4-Me), 8.75 (3 H, s, 4-Me), and 7.95 (3 H, s, Ac). Hydrolysis of this acetate gave the 17 β -ol (3; R¹ = Me, R² = H) in needles, m.p. 214–216° (from acetone–light petroleum), $[\alpha]_D^{20}$ +144° (*c* 2.0) (Found: C, 68.2; H, 8.8; S, 15.6. C₂₃H₃₆O₂S₂ requires C, 67.6; H, 8.9; S, 15.9%), ν_{\max} . 1690 cm⁻¹ (C=O), τ 9.21 (3 H, s, H₃-18), 8.82 (3 H, s, 4-Me), and 8.76 (3 H, s, 4-Me). Purification of the second fraction from alcohol–acetone gave 17 β -acetoxy-4 α -methyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one in needles (0.2 g), m.p. 209° $[\alpha]_D^{20}$ +197° (*c* 2.5) (Found: C, 65.7; H, 8.2; S, 14.7. C₂₄H₃₆O₃S₂ requires C, 66.0; H, 8.3; S, 14.7%), ν_{\max} . (CCl₄) 1735 (acetate C=O) and 1700 cm⁻¹ (C=O), τ 9.17 (3 H, s, H₃-18), 8.94 (3 H, d, *J* 6.5 Hz, 4-Me), and 7.96 (3 H, s, Ac). Hydrolysis of this acetate gave the 17 β -ol in needles (0.2 g), m.p. 228° (from acetone–light petroleum), $[\alpha]_D^{20}$ +226° (*c* 1) (Found: C, 66.8; H, 8.5; S, 16.0. C₂₂H₃₄O₂S₂ requires C, 66.9; H, 8.7; S, 16.3%), ν_{\max} . 1700 cm⁻¹ (C=O), τ 9.21 (3 H, s, H₃-18), and 8.94 (3 H, d, *J* 6.5 Hz, 4-Me).

Further methylation of this 4 α -methyl derivative (3.3 g) by the same process gave 17 β -hydroxy-4,4-dimethyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one (1.3 g) and starting material (0.7 g).

17 β -Hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (1; R¹ = R² = H).—(a) Desulphurisation of 17 β -acetoxy-4,4-dimethyl-2,2-trimethylenedithio-19-nor-5 α -androstan-3-one (0.25 g) occurred in boiling alcohol (20 ml) containing *W*-2-type Raney nickel (5 g) during 5 h. A solution of the crude product in acetone (20 ml) was oxidised with Jones reagent. Purification from acetone–light petroleum gave 17 β -acetoxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (0.15 g) in needles, m.p. 167°, $[\alpha]_D^{20}$ –25.5° (*c* 2.0) (Found: C, 76.5; H, 10.1. C₂₂H₃₄O₃ requires C, 76.3; H, 9.9%), ν_{\max} . (CCl₄) 1735 (acetate) and 1705 cm⁻¹ (C=O) τ 9.17 (3 H, s, H₃-18), 8.94 (6 H, s, 4-Me₂), and 7.95 (3 H, s, Ac). Hydrolysis of this acetate with potassium hydroxide in methanol gave (quantitatively) the 17 β -ol (1; R¹ = R² = H), in needles, m.p. 161–162° (from acetone–light petroleum) (Found: C, 79.4; H, 10.5. C₂₀H₃₂O₂ requires C, 78.9; H, 10.6%), $[\alpha]_D^{20}$ –20.4° (*c* 1.6), o.r.d. (*c* 0.28 in methanol) $[\phi]_{550}^{20}$ –110°, $[\phi]_{440}^{20}$ –200°, $[\phi]_{313}^{20}$ –1050°, $[\phi]_{270}^{20}$ +670°, $[\phi]_{265}^{20}$ +500–600° (steep portion of curve), $[\phi]_{213}^{20}$ –310°. {lit. o.r.d. (*c* 0.125 in MeOH) $[\phi]_{700}^{20}$ –76°, $[\phi]_{315}^{20}$ –974°, $[\phi]_{272.5}^{20}$ +1070°, $[\phi]_{265}^{20}$ +790°}. ν_{\max} . 1700 cm⁻¹ (C=O), τ 9.21 (3 H, s, H₃-18), 8.94 (6 H, s, 4-Me₂) (lit.⁴ m.p. 150–152°, $[\alpha]_D^{20}$ –22°).

(b) A solution of 4-methyl-19-nortestosterone⁸ (1.5 g) in ether (150 ml) was added to a solution of lithium (0.6 g) in liquid ammonia (450 ml) during 3 min. The blue solution was stirred for 2 min, and then methyl iodide (30 g) in

ether (50 ml) was added. After stirring under reflux for 1 h, the ammonia was allowed to evaporate. Isolated in the normal manner, the product was purified by chromatography from benzene on alumina; elution with benzene-ether (3:1) gave 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (0.7 g) in needles, m.p. 159° (from acetone-light petroleum), identical (i.r. and n.m.r. spectra, $[\alpha]_D^{20}$, m.p., and mixed m.p.) with the product prepared by method (a).

Oxidation of this alcohol (0.25 g) with Jones reagent gave (quantitatively) 4,4-dimethyl-19-nor-5 α -androstan-3,17-dione in needles, m.p. 128° and (after resolidification) 143° (from light petroleum) (lit.,¹⁰ m.p. 156–158°), $[\alpha]_D^{20} + 48^\circ$ (*c* 1.0), $\nu_{\max.}$ 1740 (five-membered ring C=O) and 1705 cm⁻¹ (six-membered ring C=O), μ 2.86 \pm 0.02 D (Found: C, 79.0; H, 10.0. C₂₀H₃₀O₂ requires C, 79.4; H, 10.0%).

Hydrogenation of 17 β -Hydroxy-4,4-dimethyl-19-norandrost-5-en-3-one.—The following conditions are illustrative of the various processes investigated. Prepared by the method of Bowers and Ringold,⁴ a solution of 17 β -acetoxy-4,4-dimethyl-19-norandrost-5-en-3-one (4.5 g) in acetic acid (120 ml) was added to platinum oxide (0.6 g) which had been prehydrogenated in cyclohexane (120 ml), and the mixture was shaken in hydrogen for 5 h (uptake *ca.* 750 ml). The product was isolated and oxidised with Jones reagent; a sample was removed and the remainder rehydrogenated in acetic acid (80 ml) containing platinum oxide (0.5 g) and 60% perchloric acid (0.1 ml). Absorption of 300 ml of hydrogen occurred during 3 h. The mixture was separated by an extensive application of chromatography and fractional crystallisation into the 3-ols, which were then oxidised with Jones reagent to yield (i) 17 β -acetoxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (0.8 g), identical (m.p., mixed m.p., rotation, i.r., and n.m.r.) with the previously prepared specimen and (ii) 17 β -acetoxy-4,4-dimethyl-19-nor-5 β -androstan-3-one (0.6 g), which separated from light petroleum in needles, m.p. 102°, $[\alpha]_D^{20} - 8.1^\circ$ (*c* 1.3) (Found: C, 75.9; H, 10.0. C₂₂H₃₄O₃ requires C, 76.3; H, 9.9%), $\nu_{\max.}$ (CCl₄) 1735 (acetate) and 1705 cm⁻¹ (C=O), τ 9.16 (3 H, s, H₃-18), 8.90 (3 H, s, 4-Me), 8.80 (3 H, s, 4-Me), and 7.95 (3 H, s, Ac). Saponification of this acetate gave the 17 β -ol in needles, m.p. 125°, $[\alpha]^{20} - 5.5^\circ$ (*c* 1.2), o.r.d. (*c* 0.17 in MeOH) $[\phi]_{400} - 60^\circ$, $[\phi]_{300} - 1065^\circ$, $[\phi]_{268} + 1480^\circ$, $[\phi]_{265} + 1480^\circ$, $[\phi]_{242} + 1180^\circ$, $[\phi]_{208} + 1780^\circ$ (Found: C, 78.9; H, 10.8. C₂₀H₃₂O₂ requires C, 78.9; H, 10.5%), $\nu_{\max.}$ 1700 cm⁻¹ (C=O), τ 9.21 (3 H, s, H₃-18), 8.90 (3 H, s, 4-Me), and 8.80 (3 H, s, 4-Me). Oxidation with Jones reagent gave 4,4-dimethyl-19-nor-5 β -androstan-3,17-dione, which formed needles, m.p. 105° (from light petroleum), $[\alpha]_D^{20} + 65^\circ$ (*c* 1.0) (Found: C, 79.0; H, 9.8. C₂₀H₃₀O₂ requires C, 79.4; H, 10.0%), $\nu_{\max.}$ 1740 (C=O in five-membered ring) and 1705 cm⁻¹ (C=O in six-membered ring), μ 3.06 \pm 0.02 D.

A mixture of equal quantities of 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one and the 5 β -isomer could not be separated on t.l.c. under a wide variety of conditions. The sample from the hydrogenation was saponified with methanolic potassium hydroxide: both the product and the 'synthetic' mixture were separable by g.l.c. [10 ft column of GasechromeP containing 1% SE-30; column temperature 180°C; argon (8 lb in⁻²) as carrier gas] into two components having retention times (unassigned) of 31.4 and 33.0 min.

17 β -Hydroxy-4,4,17 α -trimethyl-19-nor-5 α -androstan-3-one.

A solution of 17 β -hydroxy-4,4-dimethyl-19-nor-5 α -androstan-3-one (0.5 g) in benzene (60 ml) containing ethylene glycol (5.0 ml) and toluene-*p*-sulphonic acid (30 mg) was refluxed during 5.5 h with continuous removal of water.

3,3-Ethylenedioxy-4,4-dimethyl-19-nor-5 α -androstan-17 β -ol formed needles (0.5 g), m.p. 148° (from acetone-methanol), $[\alpha]_D^{20} + 5^\circ$ (*c* 0.1) (Found: C, 75.2; H, 10.2. C₂₂H₃₆O₃ requires C, 75.8; H, 10.4%).

Oxidation of this alcohol (0.36 g) with chromic oxide (0.4 g) in pyridine (10 ml) gave 3,3-ethylenedioxy-4,4-dimethyl-19-nor-5 α -androstan-17-one (0.31 g) in needles, m.p. 174° (from acetone), $[\alpha]_D^{20} + 14^\circ$ (*c* 0.27), $\nu_{\max.}$ 1740 cm⁻¹ (five-membered C=O) (Found: C, 76.8; H, 10.0. C₂₂H₃₄O₃ requires C, 76.2; H, 9.9%).

A solution of this ketone (0.3 g) in anisole (10 ml) was added to methylmagnesium iodide [from magnesium (0.2 g) in ether (25 ml)] and the mixture refluxed during 5 h. The resultant 17 β -hydroxy-4,4,17 α -trimethyl-19-nor-5 α -androstan-3-one (0.23 g) formed prisms (from aqueous acetone), m.p. 168°, o.r.d. (*c* 0.107 in MeOH) $[\phi]_{500} - 130^\circ$, $[\phi]_{400} - 260^\circ$, $[\phi]_{310} - 920^\circ$, $[\phi]_{225} - 1000^\circ$, *a* - 9 (Found: C, 79.0; H, 10.7. C₂₁H₃₄O₂ requires C, 79.2; H, 10.8%) (lit.,⁴ m.p. 178°, *a* - 15 for product of doubtful authenticity).

Methylation of 17 β -Hydroxy-*B*-norandrost-4-en-3-one.—Methylation of a solution of the title compound (0.5 g) in *t*-butyl alcohol (25 ml) containing potassium *t*-butoxide [from potassium (0.3 g)] and methyl iodide (0.9 ml) during 5 h at room temperature followed by purification of the product by chromatography from alumina and elution with benzene-ether gave (i) 17 β -hydroxy-4,4-dimethyl-*B*-norandrost-5-en-3-one in needles (0.15 g), m.p. 144° (from light petroleum-acetone), $[\alpha]_D^{20} - 20.4^\circ$ (*c* 1.7) (Found: C, 79.7; H, 10.1. C₂₀H₃₀O₂ requires C, 79.4; H, 10.0%), $\nu_{\max.}$ 3625 (OH) and 1705 cm⁻¹ (C=O), τ 9.18 (3 H, s, H₃-18), 8.87 (3 H, s, H₃-19), 8.87 (3 H, s, 4-Me), and 8.73 (3 H, s, 4-Me); and (ii) 17 β -hydroxy-4-methyl-*B*-norandrost-4-en-3-one (0.18 g) in needles, m.p. 140° (from light petroleum-acetone), $[\alpha]_D^{20} - 20.7^\circ$ (*c* 1.8) (Found: C, 78.5; H, 9.7. C₁₉H₂₈O₂ requires C, 78.5; H, 10.1%), τ 9.18 (3 H, s, H₃-18), 8.93 (3 H, s, H₃-19), and 8.32 (3 H, s, 4-Me).

Prepared with pyridine-acetic anhydride, 17 β -acetoxy-4,4-dimethyl-*B*-norandrost-5-en-3-one formed needles, m.p. 95° (from aqueous methanol), $[\alpha]_D^{20} - 22.7^\circ$ (*c* 1.6) (Found: C, 76.9; H, 9.4. C₂₂H₃₂O₃ requires C, 76.8; H, 9.4%). Hydrogenation of this acetate (0.3 g) in acetic acid (15 ml) and cyclohexane (15 ml) containing 60% perchloric acid (0.1 ml) and platinum oxide (0.1 g) occurred during 18 h, to yield (after oxidation with Jones reagent) 17 β -acetoxy-4,4-dimethyl-*B*-nor-5 α -androstan-3-one (0.2 g), which formed needles, m.p. 116° (from aqueous methanol), $[\alpha]_D^{20} + 62^\circ$ (*c* 1.1), o.r.d. (*c* 0.10 in MeOH) $[\phi]_{400} + 470^\circ$, $[\phi]_{313} + 1850^\circ$, $[\phi]_{283} - 350^\circ$, $[\phi]_{215} + 2220^\circ$ (Found: C, 76.0; H, 10.0%; *M*⁺ 346. C₂₂H₃₄O₃ requires C, 76.3; H, 9.9%; *M*, 346), $\nu_{\max.}$ (CCl₄) 1735 (acetate) and 1710 cm⁻¹ (C=O), τ 9.19 (3 H, s, H₃-18), 8.98 (6 H, s, 2 Me), 8.79 (3 H, s, Me), and 7.95 (3 H, s, OAc).

2-(Butylthiomethylene)-17 β -hydroxy-5 α -androstan-3-one.—A solution of 17 β -hydroxy-2-methoxymethylene-5 α -androstan-3-one (1 g) in benzene (120 ml) containing butane-1-thiol (1 ml) and toluene-*p*-sulphonic acid (0.01 g) was refluxed, with removal of water azeotropically, during 5 h. Purification of the product from ether-light petroleum gave 2-(butylthiomethylene)-17 β -hydroxy-5 α -androstan-3-one in needles (0.8 g), m.p. 98°, $[\alpha]_D^{20} - 15.9^\circ$ (*c* 1.0) (Found: C, 73.2; H, 9.9; S, 7.7. C₂₄H₃₈O₂S requires C, 73.8; H, 9.8; S, 8.2%). Prepared with pyridine-acetic anhydride, the 17 β -acetate formed needles, m.p. 147° (from methanol), $[\alpha]_D^{20} - 35.1^\circ$ (*c* 1.3) (Found: C, 72.6; H, 9.4; S, 7.5. C₂₆H₄₀O₃S requires C, 72.2; H, 9.3; S, 7.4%).

2-(*Butylthiomethylene*)-17 β -hydroxy-19-nor-5 α -androstan-3-one.—Prepared as previously from 17 β -hydroxy-2-hydroxymethylene-19-nor-5 α -androstan-3-one⁵ (1 g), 2-(*butylthiomethylene*)-17 β -hydroxy-19-nor-5 α -androstan-3-one (1.1 g) formed needles, m.p. 153° (from ether–light petroleum) $[\alpha]_D + 85.9^\circ$ (*c* 2.0) (Found: C, 73.5; H, 9.4; S, 8.7. C₂₃H₃₈O₂S requires C, 73.3; H, 9.6; S, 8.5%).

2-(*Butylthiomethylene*)-5 α -cholestan-3-one.—A suspension of 2-hydroxymethylene-5 α -cholestan-3-one (0.5 g) in methanol (8 ml) containing 60% perchloric acid (0.1 ml) was refluxed for 2 h. 2-Methoxymethylene-5 α -cholestan-3-one formed plates (0.4 g), m.p. 155° (from methanol), $[\alpha]_D + 47.0^\circ$ (*c* 1.0) [Found: C, 81.8; H, 11.1; OMe, 7.2. C₂₈H₄₅O(OMe) requires C, 81.3; H, 11.3; OMe, 7.2%]. Condensation of this methoxy-derivative (0.5 g) with butane-1-thiol (0.5 ml) in benzene (60 ml) gave 2-(*butylthiomethylene*)-5 α -cholestan-

3-one (0.5 g) in plates, m.p. 77°, $[\alpha]_D - 9.9^\circ$ (*c* 1.0) (Found: C, 78.6; H, 11.3; S, 6.6. C₃₂H₅₄OS requires C, 78.9; H, 11.2; S, 6.6%).

We are grateful to the Wellcome Trust for the provision of the Varian A-60 spectrometer on permanent loan. We thank the S.R.C. for a Research Studentship (to B. A. L.), the Nuffield Foundation for a grant in support of part of this investigation, Imperial Chemical Industries Ltd. for financial assistance, Smith Kline and French Laboratories (Philadelphia) for gifts of testosterone, 19-nortestosterone, and β -nortestosterone, Professor W. Klyne (Westfield College) for the o.r.d. measurements, Dr. G. Jones (Keele) for the g.l.c. data, and Dr. M. J. T. Robinson and Dr. A. Barnes (Oxford) for the dipole moment determinations.

[6/1121 Received, 11th June, 1976]